With increased M&A, we are likely to see a single drug manufacturing industry with strong economies of scale, diversification in product mix and, in general, a new compelling growth story.

• 随着并购，我们可能会看到一个单一制药企业的规模具有多样化的产品组合一般来说，是一个新的令人信服的成长过程。